Pacgen Biopharmaceuticals Corporation is a life science technology transfer company focused on the commercial development of novel therapeutic drug candidates up to Phase II, proof of concept efficacy in humans.
The Company identifies and sources innovative therapeutic drug candidates globally, and develops these drug candidates in accordance to the United States Food and Drug Administration regulatory standards to feed the product development pipelines of the pharmaceuticals industry.
The Company’s lead product, PAC-113, is an anti-fungal in a Phase II program for the treatment of oral Candidiasis. Pacgen recently reported positive efficacy results from its Phase IIb dose-ranging clinical trial of PAC-113. Pacgen also has an early stage research program. The most advanced candidate is a peptide therapeutic, PAC-G31P, which is being investigated in preclinical studies for its potential to treat inflammatory disease.
Pacgen holds the rights to 29 patents and 32 patent applications in the United States and other jurisdictions relating to products in its development pipeline.
Pacgen was founded in 2004 and listed on the Toronto Venture Stock Exchange in December 2006 under the symbol TSX-V:PGA. The Company’s operating facilities are located in Vancouver, British Columbia and Toronto, Ontario in Canada.
Accomplishments
- Completed acquisition of Xphase Pharmaceuticals Inc. (Q309)
- Completed private placement financing of convertible debentures C$614,500 (Q109)
- Reported positive efficacy results from its Phase IIb dose-ranging clinical trial of PAC-113 for the treatment of oral Candidiasis (Q208)
- Completed private placement financing C$903K (Q108)
- Presented poster entitled “Evaluation of a New-Host Derived Synthetic Anti-fungal Peptide (PAC-113) in the treatment of Oral Candidiasis” at the 5th Annual ACCP Meeting (Q307)
- Filed a new patent application containing claims covering the findings of the optimized formulation of PAC-113 with the US Patent and Trademark Office (Q207)
- Reported positive proof of efficacy results from its Phase I/IIa trial of PAC-113 for the treatment of oral Candidiasis (Q207)
- Completed IPO and raised approx. C$7.1M (Q406)
- Expanded Pacgen product pipeline through the completion of an acquisition or a product in-license
- Completed financing to support advancement of PAC-113 into Phase II, PAC-G31P preclinical program and new products in pipeline
- Acquired an early stage drug candidate and C$1.5M working capital from IL Therapeutics Inc. (Q206)
- In-licensed PAC-113 from Demegen Inc. (Q105)